Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (10214)	5/27/1999 11:04:00 AM
From: aknahow	Read Replies (2) \| Respond to of 17367

My point was only related to Murphy's positing of the importance of the present mortality rate for meningococcemia. He said essentially that if the rate is 15% then there might be problems proving statistical significance. (my words, not his). This is probably a correct statement. However, when dealing with >12 it becomes very difficult to see how the present standard of care anywhere is going to produce a mortality rate that low. Remember that if the 62 who died were in hospitals they were getting the standard of care normally given to patients with meningococcal sepsis. They just yet had not been enrolled, in the trial. Doctors weren't standing around doing nothing, these kids would have been treated and everybody was trying to save their lives. Had there been no trial they would have counted as part of the mortality rate for those under the present SOC. When you calculate either Roberts way or mine the mortality rate gets very close to what the existing literature says it is.